BidaskClub downgraded shares of Lannett Co Inc (NYSE:LCI) from a sell rating to a strong sell rating in a research report report published on Tuesday morning.
Other equities analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Lannett Co from a buy rating to a hold rating in a research note on Thursday, May 4th. Oppenheimer Holdings, Inc. reiterated a hold rating on shares of Lannett Co in a research note on Tuesday, May 2nd. Robert W. Baird reiterated an outperform rating and set a $18.00 target price on shares of Lannett Co in a research note on Wednesday, May 3rd. Roth Capital set a $27.00 target price on shares of Lannett Co and gave the company a buy rating in a research note on Tuesday, May 2nd. Finally, ValuEngine cut shares of Lannett Co from a buy rating to a hold rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $27.50.
Lannett Co (NYSE LCI) traded up 1.55% during midday trading on Tuesday, hitting $16.40. 769,048 shares of the stock traded hands. The company has a 50-day moving average of $20.02 and a 200-day moving average of $21.30. The stock’s market cap is $610.57 million. Lannett Co has a 1-year low of $15.75 and a 1-year high of $39.99.
WARNING: This piece was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://stocknewstimes.com/2017/08/12/lannett-co-inc-lci-stock-rating-lowered-by-bidaskclub-2.html.
Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Lannett Co by 52,610.9% in the first quarter. BlackRock Inc. now owns 3,903,766 shares of the company’s stock worth $87,250,000 after buying an additional 3,896,360 shares in the last quarter. Morgan Stanley boosted its position in shares of Lannett Co by 592.6% in the first quarter. Morgan Stanley now owns 1,339,367 shares of the company’s stock worth $29,935,000 after buying an additional 1,145,987 shares in the last quarter. Snow Capital Management LP boosted its position in shares of Lannett Co by 22.5% in the first quarter. Snow Capital Management LP now owns 3,093,435 shares of the company’s stock worth $69,138,000 after buying an additional 567,800 shares in the last quarter. Heartland Advisors Inc. acquired a new position in shares of Lannett Co during the first quarter worth about $11,175,000. Finally, Norges Bank acquired a new position in shares of Lannett Co during the fourth quarter worth about $9,295,000. Institutional investors own 95.14% of the company’s stock.
About Lannett Co
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.